(Q40938681)

English

Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus

scientific article published on July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 September 2017

Improvement of glucose and lipid metabolism with pegylated interferon-a plus ribavirin therapy in Chinese patients chronically infected with genotype 1b hepatitis C virus (English)

1 reference

Europe PubMed Central

25 September 2017

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

author name string

Shao Qing

1

1 reference

Europe PubMed Central

25 September 2017

Dong Ji

2

1 reference

Europe PubMed Central

25 September 2017

Bing Li

3

1 reference

Europe PubMed Central

25 September 2017

Fan Li

4

1 reference

Europe PubMed Central

25 September 2017

Yudong Wang

5

1 reference

Europe PubMed Central

25 September 2017

Xioaxia Niu

6

1 reference

Europe PubMed Central

25 September 2017

Binfang Ling

7

1 reference

Europe PubMed Central

25 September 2017

Yuhua Meng

8

1 reference

Europe PubMed Central

25 September 2017

George Lau

9

1 reference

Europe PubMed Central

25 September 2017

Guofeng Chen

10

1 reference

Europe PubMed Central

25 September 2017

publication date

1 July 2015

1 reference

Europe PubMed Central

25 September 2017

Annals of Saudi Medicine

1 reference

Europe PubMed Central

25 September 2017

35

1 reference

Europe PubMed Central

25 September 2017

4

1 reference

Europe PubMed Central

25 September 2017

293-297

1 reference

Europe PubMed Central

25 September 2017

Assessment of outcomes of hepatitis C treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

Hepatitis C: prevalence, transmission, screening, and prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

Non-invasive evaluation of liver fibrosis in chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

The impact of hepatic steatosis on the natural history of chronic hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

New diagnostic method for liver fibrosis and cirrhosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

Sampling variability of liver fibrosis in chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6074213

4 November 2018

Impact of Fibroscan on management of chronic viral hepatitis in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/26497709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/26497709

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.5144/0256-4947.2015.293

1 reference

Europe PubMed Central

25 September 2017

0 references

1 reference

Europe PubMed Central

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40938681&oldid=1910915891"